Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06976697 · ClinicalTrials.gov registry record · NA
Home-Based tDCS Treatment Of Major Depressive Disorder
A NA study of Major Depressive Disorder (MDD), sponsored by Sooma Medical.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06976697: Recruiting NA study of Major Depressive Disorder (MDD), sponsored by Sooma Medical.
NCT06976697 is a NA study of Major Depressive Disorder (MDD) that is actively recruiting participants, run by Sooma Medical. The registered enrollment target is 200 participants, above the 149-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (34% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06976697, a NA study of Major Depressive Disorder (MDD), is actively recruiting participants, sponsored by Sooma Medical.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The REACH-tDCS study will evaluate the safety and efficacy of a noninvasive, at-home self-administered Sooma tDCS brain stimulation treatment for Major Depressive Disorder. The study uses randomized, blinded, placebo controlled design. The participants are assessed with video interviews and self-reports during the study, which lasts for 10 weeks followed by an optional continuation period.
Primary Outcome
Mean change in depressive symptoms, measured by the Montgomery-Asberg Depression Rating Scale (MADRS) total score, from baseline to week 10. MADRS ranges from 0 to 60, with higher scores indicating more severe depression.
Conditions Studied
Interventions
- DEVICE Sham transcranial direct current stimulation
- DEVICE Transcranial direct current stimulation
Study Locations (1)
Massachusetts
- Lindus Health (virtual study site) - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-06-27 |
| Est. Completion | 2026-12-23 |
| Phase | NA |
What NCT06976697 shows while recruiting
NCT06976697 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 149-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (34% higher).
The record links to 1 condition, with Major Depressive Disorder (MDD) appearing as the primary indexed condition, and to 2 interventions - of which Sham transcranial direct current stimulation is the first listed.
NCT06976697 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06976697 about?
NCT06976697 is a clinical study titled "Home-Based tDCS Treatment Of Major Depressive Disorder". The REACH-tDCS study will evaluate the safety and efficacy of a noninvasive, at-home self-administered Sooma tDCS brain stimulation treatment for Major Depressive Disorder. The study uses randomized, blinded, placebo controlled design. The participants are assessed with video interviews and self-rep...
What is the current status of trial NCT06976697?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2025-06-27. Estimated completion is 2026-12-23.
What conditions does trial NCT06976697 study?
This clinical trial studies the following conditions: Major Depressive Disorder (MDD).
What interventions are being tested in trial NCT06976697?
The interventions under investigation include: Sham transcranial direct current stimulation (DEVICE), Transcranial direct current stimulation (DEVICE).
Who is sponsoring clinical trial NCT06976697?
This trial is sponsored by Sooma Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06976697 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder (MDD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06976697's enrollment target sits among peer trials
200 7th of 22 higher than 15 of 22 other Major Depressive Disorder (MDD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder (MDD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits
RECRUITING · NA
-
Neurofeedback to Treat Depression - 2
RECRUITING · NA
-
Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk
RECRUITING · NA
-
Improving Outcomes in Adolescent Inpatient Depression With Deep Transcranial Magnetic Stimulation
RECRUITING · NA
-
Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study
RECRUITING · NA
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI